SCHEMBL16936686

SCHEMBL16936686

COc1ccc(Cn2nnnc2-c2c(Br)ccnc2S(N)(=O)=O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.42
ALDH1A1 P00352 7/20 0.41
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.40
HTT P42858 1/20 0.39
ERCC5 P28715 1/20 0.39
FEN1 P39748 1/20 0.39
TOP2A P11388 1/20 0.38
GAA P10253 2/20 0.37
ALOX15 P16050 2/20 0.37
TSHR P16473 1/20 0.37
KDM4E B2RXH2 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
P2RX7 Q99572 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16936634 0.87 ALDH1A1 (0.37) PTGS2ALDH1A1LMNAPKMHTT
SCHEMBL18234229 0.86 PTGS2 (0.43) PTGS2ALDH1A1CYP3A4P2RX7
SCHEMBL16936260 0.82 PTGS2 (0.43) PTGS2ALDH1A1LMNAPKMHTT
SCHEMBL16936376 0.80 NPC1 (0.52) PTGS2ALDH1A1LMNATSHRL3MBTL1
SCHEMBL16936765 0.79 PTGS2 (0.42) PTGS2ALDH1A1LMNAPKMHTT
SCHEMBL16936754 0.78 PTGS2 (0.43) PTGS2ALDH1A1LMNAPKMHTT
SCHEMBL16947297 0.78 PTGS2 (0.39) PTGS2ALDH1A1LMNAPKMHTT
SCHEMBL18234226 0.76 ALDH1A1 (0.41) ALDH1A1LMNAPKMHTTERCC5
SCHEMBL16936604 0.76 P2RX7 (0.46) PTGS2ALDH1A1LMNAERCC5FEN1
SCHEMBL16936349 0.75 PTGS2 (0.41) PTGS2ALDH1A1LMNAPKMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3096754-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME (US) 2018-08-29 EP disclosed
US-9708336-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-18 US disclosed
US-9708336-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-18 US disclosed
US-9708336-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-18 US disclosed
EP-3096754-A1 METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-11-30 EP disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 US disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 US disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 US disclosed
WO-2015112441-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-30 WO disclosed
WO-2015112441-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MGAM, MGAM2, GAA PTGS2 1698/4885ALDH1A1 329/4885LMNA 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.